102940 — Kolon Life Science Share Price
- KR₩232bn
- KR₩331bn
- KR₩125bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.05 | ||
Price to Tang. Book | 2.06 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.56 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -19.78% | ||
Return on Equity | -68.04% | ||
Operating Margin | -20.79% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | KR₩m | 148,541.24 | 129,412.92 | 165,485.31 | 161,583.79 | 124,639.03 | n/a | n/a | -1.24% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | +302.83 | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
KOLON LIFE SCIENCE Inc. is a Korea-based company mainly engaged in the manufacturing of functional materials. The Company operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
Directors
- Wu Seok Lee CCE (63)
- Mun Hui Park CCE (53)
- Myeong Gwan Seo MDR (50)
- Tae Geun Choi OTH (49)
- Beom Seop Lee OTH (50)
- Sang Wu Lee OTH (48)
- Seok Jun Lee OTH (50)
- Sang Hu Park OTH (51)
- Dae Gyo Seo OTH (62)
- Wung Yeol Lee DRC (62)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- April 21st, 2000
- Public Since
- April 7th, 2009
- No. of Shareholders
- 17,080
- No. of Employees
- 432
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 12,423,387
- Address
- One&Only Tower, SEOUL, 07793
- Web
- https://www.kolonls.co.kr/
- Phone
- +82 236774150
- Auditors
- Samil Accounting Corp.
Upcoming Events for 102940
Q1 2025 Kolon Life Science Inc Earnings Release
Similar to 102940
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:38 UTC, shares in Kolon Life Science are trading at KR₩18,640. This share price information is delayed by 15 minutes.
Shares in Kolon Life Science last closed at KR₩18,640 and the price had moved by -28.53% over the past 365 days. In terms of relative price strength the Kolon Life Science share price has underperformed the FTSE Developed Asia Pacific Index by -32.1% over the past year.
The overall consensus recommendation for Kolon Life Science is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreKolon Life Science does not currently pay a dividend.
Kolon Life Science does not currently pay a dividend.
Kolon Life Science does not currently pay a dividend.
To buy shares in Kolon Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩18,640, shares in Kolon Life Science had a market capitalisation of KR₩232bn.
Here are the trading details for Kolon Life Science:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 102940
Based on an overall assessment of its quality, value and momentum Kolon Life Science is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kolon Life Science is KR₩100,000. That is 436.48% above the last closing price of KR₩18,640.
Analysts covering Kolon Life Science currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kolon Life Science. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -13.81%.
As of the last closing price of KR₩18,640, shares in Kolon Life Science were trading -11.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kolon Life Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩18,640.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kolon Life Science's management team is headed by:
- Wu Seok Lee - CCE
- Mun Hui Park - CCE
- Myeong Gwan Seo - MDR
- Tae Geun Choi - OTH
- Beom Seop Lee - OTH
- Sang Wu Lee - OTH
- Seok Jun Lee - OTH
- Sang Hu Park - OTH
- Dae Gyo Seo - OTH
- Wung Yeol Lee - DRC